244 related articles for article (PubMed ID: 16406890)
1. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.
Smith MR; Boyce SP; Moyneur E; Duh MS; Raut MK; Brandman J
J Urol; 2006 Jan; 175(1):136-9; discussion 139. PubMed ID: 16406890
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
Smith MR; Lee WC; Brandman J; Wang Q; Botteman M; Pashos CL
J Clin Oncol; 2005 Nov; 23(31):7897-903. PubMed ID: 16258089
[TBL] [Abstract][Full Text] [Related]
3. Fracture risk in Danish men with prostate cancer: a nationwide register study.
Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
[TBL] [Abstract][Full Text] [Related]
4. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
5. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.
Thorstenson A; Bratt O; Akre O; Hellborg H; Holmberg L; Lambe M; Bill-Axelson A; Stattin P; Adolfsson J
Eur J Cancer; 2012 Jul; 48(11):1672-81. PubMed ID: 22386317
[TBL] [Abstract][Full Text] [Related]
6. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
7. Therapy Insight: osteoporosis during hormone therapy for prostate cancer.
Smith MR
Nat Clin Pract Urol; 2005 Dec; 2(12):608-15; quiz 628. PubMed ID: 16474548
[TBL] [Abstract][Full Text] [Related]
8. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
9. Fracture risk following bilateral orchiectomy.
Melton LJ; Alothman KI; Khosla S; Achenbach SJ; Oberg AL; Zincke H
J Urol; 2003 May; 169(5):1747-50. PubMed ID: 12686824
[TBL] [Abstract][Full Text] [Related]
10. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
11. Risk of fracture after androgen deprivation for prostate cancer.
Walsh PC
J Urol; 2005 Sep; 174(3):929-30. PubMed ID: 16093991
[No Abstract] [Full Text] [Related]
12. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
Ulloa EW; Salup R; Patterson SG; Jacobsen PB
Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
[TBL] [Abstract][Full Text] [Related]
13. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
Curry EA; Sweeney CJ
J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
[No Abstract] [Full Text] [Related]
14. Incidence and risk factors for low trauma fractures in men with prostate cancer.
Ahlborg HG; Nguyen ND; Center JR; Eisman JA; Nguyen TV
Bone; 2008 Sep; 43(3):556-60. PubMed ID: 18585119
[TBL] [Abstract][Full Text] [Related]
15. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer.
Miyaji Y; Saika T; Yamamoto Y; Kusaka N; Arata R; Ebara S; Nasu Y; Tsushima T; Kumon H
Urology; 2004 Jul; 64(1):128-31. PubMed ID: 15245949
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
17. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.
Lee H; McGovern K; Finkelstein JS; Smith MR
Cancer; 2005 Oct; 104(8):1633-7. PubMed ID: 16116596
[TBL] [Abstract][Full Text] [Related]
18. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
19. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.
Lawrentschuk N; Fernandes K; Bell D; Barkin J; Fleshner N
J Urol; 2011 Mar; 185(3):848-54. PubMed ID: 21239017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
